2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Dose Dense Chemotherapy
Dose-dense chemotherapy represents a promising strategy in cancer treatment, aiming to maximize the effectiveness of chemotherapy drugs while minimizing treatment duration. This approach involves administering chemotherapy at shorter intervals, allowing for higher cumulative doses over a shorter period. By maintaining higher drug levels in the body, dose-dense regimens may better target rapidly dividing cancer cells, potentially enhancing tumor response rates and improving overall outcomes. Research suggests that dose-dense chemotherapy, particularly in breast cancer treatment, may lead to better survival rates and lower risk of disease recurrence compared to standard chemotherapy schedules. However, it's important to weigh the benefits against potential side effects, as higher doses may also increase the likelihood of adverse reactions such as bone marrow suppression and fatigue. Ongoing studies continue to explore the optimal dosing schedules and patient selection criteria for maximizing the benefits of dose-dense chemotherapy in various cancer types.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China